project id: TCGA-BLCA; case submitter id: TCGA-FD-A5BU; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.46; rna integrity number: 8.1; age at index: 76; days to birth: -27882; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1936; age at diagnosis: 27882; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 588.0; icd 10 code: C67.2; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lateral wall of bladder; synchronous malignancy: No; tissue or organ of origin: Lateral wall of bladder; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 3.671232876712329; pack years smoked: 67.0; is ffpe: false; composition: Not Reported; days to collection: 153; days to sample procurement: 0; initial weight: 780.0; portion submitter id: TCGA-FD-A5BU-01A-31; percent lymphocyte infiltration: 22.0; percent monocyte infiltration: 2.0; percent necrosis: 3.0; percent neutrophil infiltration: 4.0; percent normal cells: 0.0; percent stromal cells: 67.0; percent tumor cells: 30.0; percent tumor nuclei: 60.0;